Skip to content
All Sections
Subscribe Now
60°F
Sunday, September 29th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
60°F
Sunday, September 29th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Latest Trump news
Man hit, killed by fire engine
Affordable senior housing opens
Westbrook Academy reopens
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alpine Immune Sciences, Inc.
< Previous
1
2
Next >
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
May 09, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
April 10, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
April 10, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
VRTX
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
April 01, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
March 21, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 20, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
March 18, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 26, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 01, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
December 21, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
November 20, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
November 15, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
November 14, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
November 13, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
November 06, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Proposed Public Offering
November 06, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
November 03, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
November 02, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
October 30, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
October 13, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
October 04, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
September 12, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
September 05, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
August 30, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
August 22, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
May 19, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
May 11, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close